EP1988776B1 — Antiviral drugs for treatment of arenavirus infection
Assigned to Siga Technologies Inc · Expires 2012-08-08 · 14y expired
What this patent protects
Compounds, methods and pharmaceutical compositions for treating viral : infections, by administering certain novel compounds in therapeutically effective amounts are disclosed. Methods for preparing the compounds and method's using the compounds and pharmaceutical compositions th…
USPTO Abstract
Compounds, methods and pharmaceutical compositions for treating viral : infections, by administering certain novel compounds in therapeutically effective amounts are disclosed. Methods for preparing the compounds and method's using the compounds and pharmaceutical compositions thereof are also disclosed. In particular, the treatment and prophylaxis of viral infections such as caused by hemorrhagic fever viruses is disclosed, i.e. , including but not limited to, Arenaviridae (Junin, Machupo, Guanarito, Sabia, Lassa, Tacaribe, Pichinde, and LCMV), Filoviridae (Ebola and Marburg viruses), Flaviviridae (yellow fever, Omsk hemorrhagic fever and Kyasanur Forest disease viruses), and Bunyaviridae (Rift Valley fever).
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.